Improvement of Mitochondrial Toxicity in Patients Receiving a Nucleoside Reverse‐Transcriptase Inhibitor–Sparing Strategy: Results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA) | Zendy

Eugènia Negredo | Zendy; Òscar Miró | Zendy; Benjamí RodríguezSantiago | Zendy; Glòria Garrabou | Zendy; Carla Estany | Zendy; Àngels Masabeu | Zendy; Lluís Force | Zendy; Pilar Barrufet | Zendy; Josep Cucurull | Zendy; Peré Domingo | Zendy; Carlos AlonsoVillaverde | Zendy; Anna Bonjoch | Zendy; Constanza Morén | Zendy; Núria PérezÁlvarez | Zendy; Bonaventura Clotet | Zendy

Open Access

Improvement of Mitochondrial Toxicity in Patients Receiving a Nucleoside Reverse‐Transcriptase Inhibitor–Sparing Strategy: Results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA)

Author(s) -

Eugènia Negredo,

Òscar Miró,

Benjamí RodríguezSantiago,

Glòria Garrabou,

Carla Estany,

Àngels Masabeu,

Lluís Force,

Pilar Barrufet,

Josep Cucurull,

Peré Domingo,

Carlos AlonsoVillaverde,

Anna Bonjoch,

Constanza Morén,

Núria PérezÁlvarez,

Bonaventura Clotet

Publication year - 2009

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/605440

Subject(s) - mitochondrial toxicity , nucleoside reverse transcriptase inhibitor , nevirapine , medicine , reverse transcriptase inhibitor , toxicity , reverse transcriptase , lipoatrophy , pharmacology , in vivo , didanosine , virology , nucleoside analogue , nucleoside , human immunodeficiency virus (hiv) , viral disease , zidovudine , sida , antiretroviral therapy , viral load , rna , biology , biochemistry , gene , microbiology and biotechnology

Nucleoside reverse-transcriptase inhibitor (NRTI)-related mitochondrial toxicity has been suggested as a key factor in the induction of antiretroviral-related lipoatrophy. This study aimed to evaluate in vivo the effects of NRTI withdrawal on mitochondrial parameters and body fat distribution.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research